- Nachrichtendetail
-
19.06.2024 07:26:12 - dpa-AFX: AbbVie's Skyrizi Gets Approval In US For Ulcerative Colitis
WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV) Wednesday said the Food and Drug
Administration (FDA) has approved Skyrizi for the treatment of ulcerative
colitis.
The approval was based on two Phase 3 studies dubbed INSPIRE and COMMAND, in
which primary endpoint of clinical remission was achieved along with endoscopic
improvement, a key secondary endpoint.
Skyrizi is already approved in the U.S. for plaque psoriasis, psoriatic
arthritis, and Crohn's disease.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Administration (FDA) has approved Skyrizi for the treatment of ulcerative
colitis.
The approval was based on two Phase 3 studies dubbed INSPIRE and COMMAND, in
which primary endpoint of clinical remission was achieved along with endoscopic
improvement, a key secondary endpoint.
Skyrizi is already approved in the U.S. for plaque psoriasis, psoriatic
arthritis, and Crohn's disease.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
ABBVIE | A1J84E | NYSE | 200,470 | 04.11.24 22:00:10 | -3,080 | -1,51% | 200,000 | 201,280 | 204,370 | 203,550 |
